Market Overview

UPDATE: JP Morgan Downgrades Bruker Corporation to Neutral on Macro Risk

Related BRKR
Bruker Corp Has 'Great Story,' But It's Not Time To Jump In Yet
Bruker Introduces MALDI Tissuetyper Solution With New High Speed RapifleX MALDI-TOF MS System For Anatomical Pathology Research

JP Morgan cut its rating on Bruker Corporation (NASDAQ: BRKR) from Overweight to Neutral and reduced its price target from $17 to $16.

JP Morgan noted, "We are lowering our rating on BRKR from Overweight to Neutral on macro risk, given outsized exposure to Europe (41% of sales) and the potential for a slowdown in the industrial business (e.g., Veeco, CAM); we are reducing December 2012 price target from $17 to $16. … Given significant uncertainty globally, but especially in the EU (~41% of sales), we believe that it is prudent to move to the sidelines, until we see a pronounced slowing in growth in order rates."

Bruker Corporation closed at $13.39 on Tuesday.

Latest Ratings for BRKR

Nov 2015Stifel NicolausInitiates Coverage onBuy
Nov 2015Leerink SwannMaintainsOutperform
Sep 2015Morgan StanleyInitiates Coverage onEqual-weight

View More Analyst Ratings for BRKR
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Downgrades Price Target Pre-Market Outlook Analyst Ratings


Related Articles (BRKR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters